Raymond James Financial
VYGR icon

Raymond James Financial’s Voyager Therapeutics VYGR Stock Holding History

Raymond James Financial’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.6K Buy
27,896
+877
+3% +$3.33K ﹤0.01% 5176
2026
Q1 		$104K Buy
27,019
+1,952
+8% +$7.68K ﹤0.01% 5029
2025
Q4 		$98.5K Sell
25,067
-3,510
-12% -$15.5K ﹤0.01% 4928
2025
Q3 		$133K Sell
28,577
-201
-0.7% -$727 ﹤0.01% 4701
2025
Q2 		$89.5K Sell
28,778
-99,802
-78% -$322K ﹤0.01% 4929
2025
Q1 		$435K Sell
128,580
-2,925
-2% -$13.7K ﹤0.01% 4014
2024
Q4 		$746K Buy
+131,505
New +$848K ﹤0.01% 3654

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Raymond James Financial's VYGR Position: Q2 2026 in Review

Raymond James Financial increased its Voyager Therapeutics (VYGR) stake by 3.2% in Q2 2026, buying an estimated $3.33K and bringing the position to 27,896 shares worth $97.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5176.

Raymond James Financial first reported a position in VYGR in Q4 2024 and has held it in 7 quarters since. The position peaked at $746K in Q4 2024. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Raymond James Financial held 27,896 shares of Voyager Therapeutics worth $97.6K as of Q2 2026.
  • Raymond James Financial bought 877 Voyager Therapeutics shares in Q2 2026, an estimated $3.33K.
  • Voyager Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5176 holding.
  • Raymond James Financial first reported a position in Voyager Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Voyager Therapeutics position peaked at $746K in Q4 2024.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.